How Well Can a T-cell Epitope Replace Its Parent Carrier Protein? A Dose-response Study

Overview

Journal Pharm Res

Specialties Pharmacology
Pharmacy

Date 2003 May 13

PMID 12739766

Citations 1

Authors

James S Cavenaugh

Hsu-Kun Wang

Cory Hansen

Richard S Smith

James N Herron

Affiliations

Soon will be listed here.

Abstract

Purpose: This work examines the effectiveness of synthetic peptide immunogens derived from immunodominant T-cell epitopes as replacements for their intact parent protein in vaccines.

Methods: Fluorescein was conjugated to hen egg lysozyme (FL-HEL, positive control) and three synthetic peptide immunogens: (a) murine B10.A (H-2a) immunodominant T-cell epitope of HEL [FL-(T-cell epitope)]; (b) multiple antigenic peptide (MAP) multimer of this epitope ([FL-(T epitope)]n-MAP, n = 2-4); and (c) negative control MAP with T-cell epitope residues replaced with glycine [(FL-Gly18)4-MAP]. The dose response of each immunogen was examined over a 300-fold range in B10.A mice. The immune response was monitored using antifluorescein ELISA assays.

Results: FL-(T epitope)'s immune response correlated positively with dose, with maximum response comparable to that of [FL-(T epitope)]n-MAP, or FL-HEL. This trend was consistent across 1 degrees, 2 degrees, and 3 degrees responses, although interanimal variability was higher in the latter two because of an all-or-none response in mice immunized with this peptide. [FL-(T epitope)]n-MAP's immune response was consistently high and nearly dose independent, a trend observed across 1 degrees, 2 degrees, and 3 degrees responses. FL-HEL's immune response correlated negatively to dose in the 1 degrees response but was nearly dose independent in the 2 degrees and 3 degrees responses. The magnitude of these latter responses was comparable to that observed for [FL-(T epitope)]n-MAP. (FL-Gly18)4-MAP did not elicit an immune response except at the highest dose. This trend was consistent across 1 degrees, 2 degrees, and 3 degrees responses.

Conclusions: The monomeric epitope was 300-fold less potent than its parent carrier protein, but increasing immunogen valency using MAP technology compensated totally for reduced potency. (FL-Gly18)4-MAP's lack of response at all but the highest dose strongly suggests that a specific immunodominant T-cell epitope sequence for HEL is necessary for successful peptide mimicry of HEL. This work also demonstrates the importance of quality assessment of commercial MAP core resins.

Citing Articles

Partially randomized, non-blinded trial of DNA and MVA therapeutic vaccines based on hepatitis B virus surface protein for chronic HBV infection.

Cavenaugh J, Awi D, Mendy M, Hill A, Whittle H, McConkey S PLoS One. 2011; 6(2):e14626.

PMID: 21347224 PMC: 3039644. DOI: 10.1371/journal.pone.0014626.

References

OHagan D, MacKichan M, Singh M . Recent developments in adjuvants for vaccines against infectious diseases. Biomol Eng. 2001; 18(3):69-85. DOI: 10.1016/s1389-0344(01)00101-0. View

Tam J . Synthetic peptide vaccine design: synthesis and properties of a high-density multiple antigenic peptide system. Proc Natl Acad Sci U S A. 1988; 85(15):5409-13. PMC: 281766. DOI: 10.1073/pnas.85.15.5409. View

Chai S, Clavijo P, Tam J, Zavala F . Immunogenic properties of multiple antigen peptide systems containing defined T and B epitopes. J Immunol. 1992; 149(7):2385-90. View

Fishman M, Perelson A . Lymphocyte memory and affinity selection. J Theor Biol. 1995; 173(3):241-62. DOI: 10.1016/s0022-5193(95)80003-4. View

Munesinghe D, Clavijo P, Calle M, Nussenzweig R, Nardin E . Immunogenicity of multiple antigen peptides (MAP) containing T and B cell epitopes of the repeat region of the P. falciparum circumsporozoite protein. Eur J Immunol. 1991; 21(12):3015-20. DOI: 10.1002/eji.1830211217. View

Tam J, Clavijo P, Lu Y, NUSSENZWEIG V, Nussenzweig R, Zavala F . Incorporation of T and B epitopes of the circumsporozoite protein in a chemically defined synthetic vaccine against malaria. J Exp Med. 1990; 171(1):299-306. PMC: 2187660. DOI: 10.1084/jem.171.1.299. View

Larsson A, Wejaker P, Forsberg P, Lindahl T . Chicken antibodies: a tool to avoid interference by complement activation in ELISA. J Immunol Methods. 1992; 156(1):79-83. DOI: 10.1016/0022-1759(92)90013-j. View

Sjolander A, Drane D, Maraskovsky E, Scheerlinck J, Suhrbier A, Tennent J . Immune responses to ISCOM formulations in animal and primate models. Vaccine. 2001; 19(17-19):2661-5. DOI: 10.1016/s0264-410x(00)00497-7. View

LANGER , Cleland , Hanes . New advances in microsphere-based single-dose vaccines. Adv Drug Deliv Rev. 2000; 28(1):97-119. DOI: 10.1016/s0169-409x(97)00053-7. View

10.

McLean G, Owsianka A, Marsden H . Generation of anti-peptide and anti-protein sera. Effect of peptide presentation on immunogenicity. J Immunol Methods. 1991; 137(2):149-57. DOI: 10.1016/0022-1759(91)90019-c. View

11.

Briand J, Barin C, Van Regenmortel M, Muller S . Application and limitations of the multiple antigen peptide (MAP) system in the production and evaluation of anti-peptide and anti-protein antibodies. J Immunol Methods. 1992; 156(2):255-65. DOI: 10.1016/0022-1759(92)90033-p. View

12.

Keah H, Kecorius E, Hearn M . Direct synthesis and characterisation of multi-dendritic peptides for use as immunogens. J Pept Res. 1998; 51(1):2-8. DOI: 10.1111/j.1399-3011.1998.tb00410.x. View

13.

Francis M, Hastings G, Brown F, McDermed J, Lu Y, Tam J . Immunological evaluation of the multiple antigen peptide (MAP) system using the major immunogenic site of foot-and-mouth disease virus. Immunology. 1991; 73(3):249-54. PMC: 1384538. View

14.

Lu Y, Clavijo P, Galantino M, Shen Z, Liu W, Tam J . Chemically unambiguous peptide immunogen: preparation, orientation and antigenicity of purified peptide conjugated to the multiple antigen peptide system. Mol Immunol. 1991; 28(6):623-30. DOI: 10.1016/0161-5890(91)90131-3. View

15.

Carlander D, Larsson A . Avian antibodies can eliminate interference due to complement activation in ELISA. Ups J Med Sci. 2002; 106(3):189-95. DOI: 10.3109/2000-1967-145. View

16.

Mowat A, Steel M, Worthey E, Kewin P, Garside P . Inactivation of Th1 and Th2 cells by feeding ovalbumin. Ann N Y Acad Sci. 1996; 778:122-32. DOI: 10.1111/j.1749-6632.1996.tb21121.x. View

17.

Bercovici N, Delon J, Cambouris C, Escriou N, Debre P, Liblau R . Chronic intravenous injections of antigen induce and maintain tolerance in T cell receptor-transgenic mice. Eur J Immunol. 1999; 29(1):345-54. DOI: 10.1002/(SICI)1521-4141(199901)29:01<345::AID-IMMU345>3.0.CO;2-K. View

18.

GAMMON G, Geysen H, Apple R, PICKETT E, Palmer M, Ametani A . T cell determinant structure: cores and determinant envelopes in three mouse major histocompatibility complex haplotypes. J Exp Med. 1991; 173(3):609-17. PMC: 2118818. DOI: 10.1084/jem.173.3.609. View

19.

Bormer O . Interference of complement with the binding of carcinoembryonic antigen to solid-phase monoclonal antibodies. J Immunol Methods. 1989; 121(1):85-93. DOI: 10.1016/0022-1759(89)90423-7. View

20.

Hu K, Lovgren-Bengtsson K, Morein B . Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev. 2001; 51(1-3):149-59. DOI: 10.1016/s0169-409x(01)00165-x. View